Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

RethiNKing which immune cells are the best weapon against lung cancer
(Walter and Eliza Hall Institute) Immune cells called 'natural killer' (NK) cells could be a powerful weapon for fighting lung cancer, according to Melbourne researchers.Studying preclinical and patient samples of small cell lung cancer (SCLC), the Walter and Eliza Hall Institute team revealed that NK cells - but not T cells - are essential for slowing the aggressive spread of the cancer. 'Supercharging' the NK cells further boosted their cancer-fighting abilities. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 1, 2020 Category: Biology Source Type: news

Oncotarget: Correction of NSE concentration improves diagnostic accuracy in lung cancer
(Impact Journals LLC) Oncotarget Volume 11, Issue 27 published " Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer " by Genet et al. which reported that this study aimed to develop a hemolysis correction equation and evaluate its role in small-cell lung cancer (SCLC) diagnostics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Lurbinectedin (Zepzelca) Approved for Metastatic SCLC Lurbinectedin (Zepzelca) Approved for Metastatic SCLC
The FDA has granted accelerated approval for use of this new drug in metastatic small cell lung cancer (SCLC) that has progressed after or during treatment with platinum-based chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Up-Front Stereotactic Radiosurgery an Option for SCLC Brain Mets Up-Front Stereotactic Radiosurgery an Option for SCLC Brain Mets
The trade-offs with first-line SRS without WBRT include a shorter time to new brain metastases without an apparent difference in overall survival, according to the FIRE-SCLC study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Largest ever study of radiosurgery for brain metastases from small cell lung cancer
(University of Colorado Anschutz Medical Campus) The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit with whole-brain radiation therapy compared with radiosurgery in patients with small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2020 Category: Cancer & Oncology Source Type: news

Medicaid Not Associated with Improved Survival in Patients with SCLC
These findings suggest that there are significant outcome inequalities for patients with small cell lung cancer which are relevant to the policy debate on Medicaid expansion under the Affordable Care Act. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Use of Prophylactic Cranial Irradiation in Patients with Limited Stage SCLC
Researchers found that using prophylactic cranial irradiation after thoracic radiation in patients with limited-stage small cell lung cancer undergoing contemporary head imaging is not associated with a decrease in risk of developing new brain metastasis. (Source: CancerNetwork)
Source: CancerNetwork - April 23, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2020 Category: Drugs & Pharmacology Source Type: news

FDA OKs Durvalumab Combo for Extensive-Stage SCLC FDA OKs Durvalumab Combo for Extensive-Stage SCLC
The immunotherapy is now approved for use in patients with small cell lung cancer (SCLC); it was already approved for non-small cell lung cancer (NSCLC).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 30, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Durvalumab Plus Standard of Care Chemo for Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi) as a first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide plus either carboplatin or cisplatin. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

New connections: Targeted treatment options for SCLC
Various studies reveal how we might effectively treat small cell lung cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - February 11, 2020 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Revealed an alteration related to the loss of effectiveness of a treatment in lung cancer
(Josep Carreras Leukaemia Research Institute) Researchers from IJC reveal that non-smoking patients with lung cancer that have an alteration in RB1 and are treated with EGFR inhibitors, acquire resistance to treatment through the mechanism of histopathological transformation, either to non-small cell lung cancer (SCLC) or SLCL combined with a transformation to squamous cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 23, 2020 Category: Cancer & Oncology Source Type: news

Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). (Source: World Pharma News)
Source: World Pharma News - November 29, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 6, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
MERU, a Phase 3 placebo-controlled trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit for patients receiving Rova-T at the interim analysis Independent Data Monitoring... Biopharmaceuticals, Oncology AbbVie, Rova-T, Rovalpituzumab Tesirine, small-cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 29, 2019 Category: Pharmaceuticals Source Type: news

Use of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer May Be Dropping Use of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer May Be Dropping
Prophylactic cranial irradiation (PCI) for patients with extensive-stage small-cell lung cancer (ES-SCLC) appears to have become less common in the U.S., according to a new survey.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - July 26, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
KENILWORTH, N.J.--(BUSINESS WIRE)--June 18, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2019 Category: Drugs & Pharmacology Source Type: news

Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Anna F. Farago, MD, PhD Source Type: news

Twice-Daily Radiation for SCLC Tied to Higher Risk of Brain Metastases in Chinese Patients Twice-Daily Radiation for SCLC Tied to Higher Risk of Brain Metastases in Chinese Patients
In patients treated for small-cell lung cancer (SCLC) in China, twice-daily radiotherapy was associated with more brain metastases than once-daily radiation, a retrospective study found.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 3, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer
(European Society for Medical Oncology) Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress (ELCC) 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news

AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
Antitumor activity promising; objective response rate 19.3 percent for patients with incurable, advanced SCLC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 2, 2019 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Conference News, Source Type: news

AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
TUESDAY, April 2, 2019 -- For patients with advanced small cell lung cancer (SCLC), pembrolizumab shows antitumor activity with durable responses, according to a study presented at the annual meeting of the American Association for Cancer Research,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2019 Category: Pharmaceuticals Source Type: news

Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
(American Association for Cancer Research) The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Focus on immunotherapy and patient perspective at IASLC 2019 Small Cell Lung Cancer Meeting
(International Association for the Study of Lung Cancer) While non-small cell lung cancer (NSCLC) is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly. In order to capitalize on these recent developments, researchers who focus on small cell lung cancer (SCLC) will gather in New York City at Memorial Sloan Kettering Cancer April 3-5, 2019, for the IASLC 2019 Small Cell Lung Cancer Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2019 Category: International Medicine & Public Health Source Type: news

Lung cancer patient channels diagnosis into lifetime activism
(International Association for the Study of Lung Cancer) The Third Biennial IASLC-sponsored Small Cell Lung Cancer Workshop will be held at Memorial Sloan Kettering Cancer Center in New York City, April 3-5, 2019, and will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: World Pharma News)
Source: World Pharma News - March 20, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Tecentriq Approved for Small Cell Lung Cancer
TUESDAY, March 19, 2019 -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC). The drug has been approved as a first-line treatment for the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 19, 2019 Category: General Medicine Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - March 19, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news

Prophylactic cranial irradiation: Improvements for advanced NSCLC
(NRG Oncology) Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: news

Sharp Drop in PCI Use for Extensive-Stage SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news

Sharp Drop in Prophylactic Brain Irradiation in SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news

Researchers develop human cell-based model to study small cell lung cancer
(Rockefeller University Press) Researchers from Weill Cornell Medicine have used human embryonic stem cells to create a new model system that allows them to study the initiation and progression of small cell lung cancer (SCLC). The study, which will be published February 8, 2019 in the Journal of Experimental Medicine, reveals the distinct roles played by two critical tumor suppressor genes that are commonly mutated in these highly lethal cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 8, 2019 Category: Biology Source Type: news

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcr...
Source: Signal Transduction Knowledge Environment - February 5, 2019 Category: Science Authors: Augert, A., Eastwood, E., Ibrahim, A. H., Wu, N., Grunblatt, E., Basom, R., Liggitt, D., Eaton, K. D., Martins, R., Poirier, J. T., Rudin, C. M., Milletti, F., Cheng, W.-Y., Mack, F., MacPherson, D. Tags: STKE Research Articles Source Type: news

Patients With Lower-Stage Small-Cell Lung Cancer Do Better Patients With Lower-Stage Small-Cell Lung Cancer Do Better
Patients with stage I to II small-cell lung cancer (SCLC) treated with chemoradiotherapy have better outcome than those with stage III disease, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

Age Just a Number for Older, Fit Limited-Stage SCLC Patients
(MedPage Today) -- Standard chemoradiotherapy proved just as effective compared with younger patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 9, 2018 Category: Hematology Source Type: news

Concurrent chemo-radiotherapy should be a treatment option for elderly patients with LS-S
(International Association for the Study of Lung Cancer) Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy. Concurrent chemo-radiotherapy should be a treatment option for fit patients aged 70 years or older. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2018 Category: Cancer & Oncology Source Type: news

Nanopore technology with DNA computing easily detects microRNA patterns of lung cancer
(Tokyo University of Agriculture and Technology) Researchers at Tokyo University of Agriculture and Technology (TUAT) have developed a simple technique that allows detection of two independent microRNAs as an early diagnosis marker of Small Cell Lung Cancer (SCLC) , which is very aggressive. In this technique, they combined nanopore and DNA computing technologies as rapid and label-free detection. This method, therefore, could help to identify SCLC in the early stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2018 Category: Cancer & Oncology Source Type: news

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. Here, we demonstrate that a common set of defined oncogenic drivers reproducibly reprograms normal human prostate and lung epithelial cells to small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. We ide...
Source: ScienceNOW - October 4, 2018 Category: Science Authors: Park, J. W., Lee, J. K., Sheu, K. M., Wang, L., Balanis, N. G., Nguyen, K., Smith, B. A., Cheng, C., Tsai, B. L., Cheng, D., Huang, J., Kurdistani, S. K., Graeber, T. G., Witte, O. N. Tags: Medicine, Diseases reports Source Type: news